Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:veterinary_medicine
|
| gptkbp:activeIngredient |
afoxolaner
|
| gptkbp:administeredBy |
gptkb:dog
|
| gptkbp:approvalYear |
2013
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:contraindication |
use in cats
|
| gptkbp:countryOfOperation |
gptkb:Australia
gptkb:Canada gptkb:United_States |
| gptkbp:form |
monthly
chewable tablet |
| https://www.w3.org/2000/01/rdf-schema#label |
NexGard
|
| gptkbp:manufacturer |
gptkb:Boehringer_Ingelheim
|
| gptkbp:mechanismOfAction |
inhibits GABA-gated chloride channels in insects and acarines
|
| gptkbp:notableFauna |
gptkb:dog
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
vomiting
diarrhea anorexia lethargy |
| gptkbp:spectrumOfActivity |
fleas
ticks |
| gptkbp:usedFor |
flea control
tick control |
| gptkbp:bfsParent |
gptkb:Boehringer_Ingelheim_Animal_Health
|
| gptkbp:bfsLayer |
7
|